Fundai

Jaber Ebne Hayyan Pharmaceutical Company (DJABER) income statement

Operating revenue through to net profit and earnings per share

Ticker
DJABER
Industry
Pharmaceuticals
Market
Tehran Stock Exchange

Latest periods

Latest 9-month periods, in million rials
ItemTo 1405/06/31To 1404/06/31To 1403/06/31To 1402/09/30To 1401/09/30To 1400/09/30
Operating revenue42,079,42711,024,62610,535,32610,634,7205,617,8164,056,974
Cost of operating revenue-23,277,368-7,843,743-8,008,404-7,758,072-3,888,903-2,757,019
Gross profit (loss)18,802,0593,180,8832,526,9222,876,6481,728,9131,299,955
Selling, general and administrative expenses-2,383,141-1,100,750-998,179-824,782-496,345-311,713
Other income82,60973,99486,42989,15734,67321,434
Other expenses-4,647-9,422-92,927-257,158-23,999-8,996
Operating profit (loss)16,496,8802,144,7051,522,2451,883,8651,243,2421,000,680
Finance costs-648,480-375,351-1,158,886-1,021,831-517,686-387,857
Other non-operating income and expenses2,423,8931,161,4553,726,858946,6451,256,547400,616
Profit (loss) from continuing operations before tax18,272,2932,930,8094,090,2171,808,6791,982,1031,013,439
Current year tax-3,565,890-320,064-81,756-190,898-147,180-185,937
Net profit (loss) from continuing operations14,706,4032,610,7454,008,4611,617,7811,834,923806,414
Net profit (loss)14,706,4032,610,7454,008,4611,617,7811,834,923806,414
Basic earnings (loss) per share6,697 rials1,151 rials1,767 rials713 rials809 rials356 rials
Net earnings (loss) per share, rials6,485 rials1,152 rials1,768 rials714 rials810 rials356 rials
Capital2,268,0002,268,0002,268,0002,268,0002,268,0002,268,000

Reporting periods

97 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.